On March 25th, the group standard titled " Culture and Identification of Patient-Derived Organoids for Intrahepatic Cholangiocarcinoma" (T/QMHIPA 001—2024), co-drafted by the team of DongWangand JingLifrom theInstitute forTranslational Medicine of Medical Collageandled by Haier International Cell Bank (Qingdao Haier Biotechnology Co., Ltd.), was officially released by the Qingdao Health and Elderly Care Industry Promotion Association, marking a significant breakthrough in the medicine-education-research-industrialization field.

Organoid technology has rapidly emerged in recent years, providing a new technical platform for tumor biology research, drug screening, and precision medicine. The team of DongWangand JingLifrom theInstitute forTranslational Medicine has long been dedicated to the translational research of adult stem cells and organoids. In recent years, they have closely collaborated with our affiliated hospitals, Qingdao Municipal Hospital affiliated with Qingdao University, and Haier Biotechnology to promote the standardization of organoid technology and actively explore new ideas and models for personalized precision medicine.